Cargando…
Clinical and Microbiological Outcomes and Follow-Up of Secondary Bacterial and Fungal Infections among Critically Ill COVID-19 Adult Patients Treated with and without Immunomodulation: A Prospective Cohort Study
Background: Nearly 10% of COVID-19 cases will require admission to the intensive care unit (ICU). Our aim was to assess the clinical and microbiological outcomes of secondary infections among critically ill COVID-19 adult patients treated with/without immunomodulation. Methods: A prospective observa...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10376198/ https://www.ncbi.nlm.nih.gov/pubmed/37508292 http://dx.doi.org/10.3390/antibiotics12071196 |
_version_ | 1785079211518590976 |
---|---|
author | Szabó, Bálint Gergely Czél, Eszter Nagy, Imola Korózs, Dorina Petrik, Borisz Marosi, Bence Gáspár, Zsófia Rajmon, Martin Di Giovanni, Márk Vályi-Nagy, István Sinkó, János Lakatos, Botond Bobek, Ilona |
author_facet | Szabó, Bálint Gergely Czél, Eszter Nagy, Imola Korózs, Dorina Petrik, Borisz Marosi, Bence Gáspár, Zsófia Rajmon, Martin Di Giovanni, Márk Vályi-Nagy, István Sinkó, János Lakatos, Botond Bobek, Ilona |
author_sort | Szabó, Bálint Gergely |
collection | PubMed |
description | Background: Nearly 10% of COVID-19 cases will require admission to the intensive care unit (ICU). Our aim was to assess the clinical and microbiological outcomes of secondary infections among critically ill COVID-19 adult patients treated with/without immunomodulation. Methods: A prospective observational cohort study was performed between 2020 and 2022 at a single ICU. The diagnosis and severity classification were established by the ECDC and WHO criteria, respectively. Eligible patients were included consecutively at admission, and followed for +30 days post-inclusion. Bloodstream-infections (BSIs), ventilator-associated bacterial pneumonia (VAP), and COVID-19-associated invasive pulmonary aspergillosis (CAPA) were defined according to international guidelines. Patient stratification was performed by immunomodulatory therapy administration (dexamethasone, tocilizumab, baricitinib/ruxolitinib). The primary outcome was any microbiologically confirmed major infectious complication, secondary outcomes were invasive mechanical ventilation (IMV) requirement and all-cause mortality. Results: Altogether, 379 adults were included. At baseline, 249/379 (65.7%) required IMV and 196/379 (51.7%) had a cytokine storm. At +30 days post-inclusion, the rate of any microbiologically confirmed major infectious complication was 151/379 (39.8%), IMV requirement and all-cause mortality were 303/379 (79.9%) and 203/379 (53.6%), respectively. There were no statistically significant outcome differences after stratification. BSI, VAP, and CAPA episodes were mostly caused by Enterococcus faecalis (27/124, 22.1%), Pseudomonas aeruginosa (26/91, 28.6%), and Aspergillus fumigatus (20/20, 100%), respectively. Concerning the primary outcome, Kaplan–Meier analysis showed similar probability distributions between the treatment subgroups (118/299, 39.5% vs. 33/80, 41.3%, log-rank p = 0.22), and immunomodulation was not retained as its independent predictor in multivariate logistic regression. Conclusions: Secondary infections among critically ill COVID-19 adult patients represent a relevant burden, probably irrespective of immunomodulatory treatment. |
format | Online Article Text |
id | pubmed-10376198 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103761982023-07-29 Clinical and Microbiological Outcomes and Follow-Up of Secondary Bacterial and Fungal Infections among Critically Ill COVID-19 Adult Patients Treated with and without Immunomodulation: A Prospective Cohort Study Szabó, Bálint Gergely Czél, Eszter Nagy, Imola Korózs, Dorina Petrik, Borisz Marosi, Bence Gáspár, Zsófia Rajmon, Martin Di Giovanni, Márk Vályi-Nagy, István Sinkó, János Lakatos, Botond Bobek, Ilona Antibiotics (Basel) Article Background: Nearly 10% of COVID-19 cases will require admission to the intensive care unit (ICU). Our aim was to assess the clinical and microbiological outcomes of secondary infections among critically ill COVID-19 adult patients treated with/without immunomodulation. Methods: A prospective observational cohort study was performed between 2020 and 2022 at a single ICU. The diagnosis and severity classification were established by the ECDC and WHO criteria, respectively. Eligible patients were included consecutively at admission, and followed for +30 days post-inclusion. Bloodstream-infections (BSIs), ventilator-associated bacterial pneumonia (VAP), and COVID-19-associated invasive pulmonary aspergillosis (CAPA) were defined according to international guidelines. Patient stratification was performed by immunomodulatory therapy administration (dexamethasone, tocilizumab, baricitinib/ruxolitinib). The primary outcome was any microbiologically confirmed major infectious complication, secondary outcomes were invasive mechanical ventilation (IMV) requirement and all-cause mortality. Results: Altogether, 379 adults were included. At baseline, 249/379 (65.7%) required IMV and 196/379 (51.7%) had a cytokine storm. At +30 days post-inclusion, the rate of any microbiologically confirmed major infectious complication was 151/379 (39.8%), IMV requirement and all-cause mortality were 303/379 (79.9%) and 203/379 (53.6%), respectively. There were no statistically significant outcome differences after stratification. BSI, VAP, and CAPA episodes were mostly caused by Enterococcus faecalis (27/124, 22.1%), Pseudomonas aeruginosa (26/91, 28.6%), and Aspergillus fumigatus (20/20, 100%), respectively. Concerning the primary outcome, Kaplan–Meier analysis showed similar probability distributions between the treatment subgroups (118/299, 39.5% vs. 33/80, 41.3%, log-rank p = 0.22), and immunomodulation was not retained as its independent predictor in multivariate logistic regression. Conclusions: Secondary infections among critically ill COVID-19 adult patients represent a relevant burden, probably irrespective of immunomodulatory treatment. MDPI 2023-07-17 /pmc/articles/PMC10376198/ /pubmed/37508292 http://dx.doi.org/10.3390/antibiotics12071196 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Szabó, Bálint Gergely Czél, Eszter Nagy, Imola Korózs, Dorina Petrik, Borisz Marosi, Bence Gáspár, Zsófia Rajmon, Martin Di Giovanni, Márk Vályi-Nagy, István Sinkó, János Lakatos, Botond Bobek, Ilona Clinical and Microbiological Outcomes and Follow-Up of Secondary Bacterial and Fungal Infections among Critically Ill COVID-19 Adult Patients Treated with and without Immunomodulation: A Prospective Cohort Study |
title | Clinical and Microbiological Outcomes and Follow-Up of Secondary Bacterial and Fungal Infections among Critically Ill COVID-19 Adult Patients Treated with and without Immunomodulation: A Prospective Cohort Study |
title_full | Clinical and Microbiological Outcomes and Follow-Up of Secondary Bacterial and Fungal Infections among Critically Ill COVID-19 Adult Patients Treated with and without Immunomodulation: A Prospective Cohort Study |
title_fullStr | Clinical and Microbiological Outcomes and Follow-Up of Secondary Bacterial and Fungal Infections among Critically Ill COVID-19 Adult Patients Treated with and without Immunomodulation: A Prospective Cohort Study |
title_full_unstemmed | Clinical and Microbiological Outcomes and Follow-Up of Secondary Bacterial and Fungal Infections among Critically Ill COVID-19 Adult Patients Treated with and without Immunomodulation: A Prospective Cohort Study |
title_short | Clinical and Microbiological Outcomes and Follow-Up of Secondary Bacterial and Fungal Infections among Critically Ill COVID-19 Adult Patients Treated with and without Immunomodulation: A Prospective Cohort Study |
title_sort | clinical and microbiological outcomes and follow-up of secondary bacterial and fungal infections among critically ill covid-19 adult patients treated with and without immunomodulation: a prospective cohort study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10376198/ https://www.ncbi.nlm.nih.gov/pubmed/37508292 http://dx.doi.org/10.3390/antibiotics12071196 |
work_keys_str_mv | AT szabobalintgergely clinicalandmicrobiologicaloutcomesandfollowupofsecondarybacterialandfungalinfectionsamongcriticallyillcovid19adultpatientstreatedwithandwithoutimmunomodulationaprospectivecohortstudy AT czeleszter clinicalandmicrobiologicaloutcomesandfollowupofsecondarybacterialandfungalinfectionsamongcriticallyillcovid19adultpatientstreatedwithandwithoutimmunomodulationaprospectivecohortstudy AT nagyimola clinicalandmicrobiologicaloutcomesandfollowupofsecondarybacterialandfungalinfectionsamongcriticallyillcovid19adultpatientstreatedwithandwithoutimmunomodulationaprospectivecohortstudy AT korozsdorina clinicalandmicrobiologicaloutcomesandfollowupofsecondarybacterialandfungalinfectionsamongcriticallyillcovid19adultpatientstreatedwithandwithoutimmunomodulationaprospectivecohortstudy AT petrikborisz clinicalandmicrobiologicaloutcomesandfollowupofsecondarybacterialandfungalinfectionsamongcriticallyillcovid19adultpatientstreatedwithandwithoutimmunomodulationaprospectivecohortstudy AT marosibence clinicalandmicrobiologicaloutcomesandfollowupofsecondarybacterialandfungalinfectionsamongcriticallyillcovid19adultpatientstreatedwithandwithoutimmunomodulationaprospectivecohortstudy AT gasparzsofia clinicalandmicrobiologicaloutcomesandfollowupofsecondarybacterialandfungalinfectionsamongcriticallyillcovid19adultpatientstreatedwithandwithoutimmunomodulationaprospectivecohortstudy AT rajmonmartin clinicalandmicrobiologicaloutcomesandfollowupofsecondarybacterialandfungalinfectionsamongcriticallyillcovid19adultpatientstreatedwithandwithoutimmunomodulationaprospectivecohortstudy AT digiovannimark clinicalandmicrobiologicaloutcomesandfollowupofsecondarybacterialandfungalinfectionsamongcriticallyillcovid19adultpatientstreatedwithandwithoutimmunomodulationaprospectivecohortstudy AT valyinagyistvan clinicalandmicrobiologicaloutcomesandfollowupofsecondarybacterialandfungalinfectionsamongcriticallyillcovid19adultpatientstreatedwithandwithoutimmunomodulationaprospectivecohortstudy AT sinkojanos clinicalandmicrobiologicaloutcomesandfollowupofsecondarybacterialandfungalinfectionsamongcriticallyillcovid19adultpatientstreatedwithandwithoutimmunomodulationaprospectivecohortstudy AT lakatosbotond clinicalandmicrobiologicaloutcomesandfollowupofsecondarybacterialandfungalinfectionsamongcriticallyillcovid19adultpatientstreatedwithandwithoutimmunomodulationaprospectivecohortstudy AT bobekilona clinicalandmicrobiologicaloutcomesandfollowupofsecondarybacterialandfungalinfectionsamongcriticallyillcovid19adultpatientstreatedwithandwithoutimmunomodulationaprospectivecohortstudy |